Tryptamine Therapeutics (ASX:TYP) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tryptamine Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was A$1.81 Mil. Tryptamine Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Tryptamine Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Tryptamine Therapeutics's current FCF Yield % is -29.54%.

The historical rank and industry rank for Tryptamine Therapeutics's FCF Margin % or its related term are showing as below:

ASX:TYP' s FCF Margin % Range Over the Past 10 Years
Min: -9653 Med: -5160.19 Max: -560
Current: -560

During the past 6 years, the highest FCF Margin % of Tryptamine Therapeutics was -560.00%. The lowest was -9653.00%. And the median was -5160.19%.

ASX:TYP's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -143.92 vs ASX:TYP: -560.00

Tryptamine Therapeutics FCF Margin % Historical Data

The historical data trend for Tryptamine Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics FCF Margin % Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-9,653.00

-667.37

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial						-	-	-244.90	-1,271.37	-

Competitive Comparison of Tryptamine Therapeutics's FCF Margin %

For the Biotechnology subindustry, Tryptamine Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's FCF Margin % falls into.

Tryptamine Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tryptamine Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-4.131	/	0.619
	=	-667.37 %

Tryptamine Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1.814	/	0
	=	%

Tryptamine Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines